Upatinib is a selective JAK inhibitor developed and produced by AbbVie Corporation in the United States, mainly used to treat various inflammatory diseases.

1、 Drug name and main ingredients

1. Drug generic name: Upadacitinib

2. Product Name: RINVOQ ®/ RINVOQLQ ®。

3. The main ingredient is Upatinib.

2、 Indications

1. Adult moderate to severe rheumatoid arthritis (insufficient response or intolerance to TNF inhibitors)

2. Active psoriatic arthritis in adults and children aged 2 and above (with insufficient or intolerant response to TNF inhibitors)

3. Adolescents over 12 years old and adults with moderate to severe atopic dermatitis (when systemic treatment is poorly controlled)

4. Adult moderate to severe ulcerative colitis and Crohn's disease (inadequate or intolerant to TNF inhibitors)

5. Adult active ankylosing spondylitis and non radiological axial spondyloarthritis (insufficient or intolerant response to TNF inhibitors)

6. Childhood idiopathic arthritis with multiple joints in children aged 2 and above (insufficient or intolerant to TNF inhibitors)

3、 Specifications and characteristics

15mg: Tablets

4、 Usage and dosage

1. Rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis: 15mg once daily

2. Atopic dermatitis: 15mg once daily, if the therapeutic effect is insufficient, it can be increased to 30mg once daily

3. Ulcerative colitis induction period: 45mg once daily (8 weeks), maintenance period: 15mg once daily

4. Crohn's disease induction period: 45mg once daily (12 weeks), maintenance period: 15mg once daily

5. Children's dosage: Adjust according to weight (oral solution needs to be taken in 2 doses)

5、 Dose adjustment

1. Liver dysfunction: Prohibited for severe liver damage; Mild to moderate liver damage, ulcerative colitis/Crohn's disease require reduction in dosage

2. Renal insufficiency: Severe renal damage (eGFR15-29mL/min) requires dose adjustment, and end-stage renal disease is contraindicated

3. Drug interactions: Strong CYP3A4 inhibitors (such as ketoconazole) should be reduced in dosage, and strong CYP3A4 inducers (such as rifampicin) should be avoided in combination

6、 Medication precautions

1. Medication time: Tablets can be taken daily at a fixed time and can be taken with food or on an empty stomach; Oral liquid twice a day

2. Omission treatment: Take the medication as soon as possible after discovery. If it is close to the next medication time, skip and do not double the dosage

3. Vomiting treatment: If vomiting occurs after taking the medication, there is no need to take it again. Take the next dose according to the original plan

4. Whole tablet ingestion: Tablets should not be broken, chewed, or crushed

7、 Medication for special populations

1. Pregnant women: May cause fetal malformation, confirm pregnancy status before medication, effective contraception until 4 weeks after discontinuation of medication

2. Breastfeeding period: Do not breastfeed within 6 days after discontinuation of medication

3. Older adults: increased risk of infection and malignant tumors

4. Children: Safety not established for children under 2 years old

8、 Adverse reactions

1. Common adverse reactions: upper respiratory tract infection, acne, herpes virus infection, headache, elevated CPK, decreased neutrophils

2. Serious adverse reactions: severe infections (tuberculosis, fungi, bacteria), cardiovascular events (myocardial infarction, stroke), malignant tumors (lymphoma, lung cancer), thrombosis (DVT, PE), gastrointestinal perforation

9、 Contraindications

Prohibited for individuals allergic to Upatinib or any excipients

10、 Drug interactions

1. Prohibition of combination use: other JAK inhibitors, biologics, strong immunosuppressants (such as azathioprine)

2. Dose adjustment required: Strong CYP3A4 inhibitors (such as ketoconazole)

3. Vaccines: Avoid using live vaccines

11、 Storage method

Tablets: Store in the original bottle at 2-25 ° C, moisture-proof

12、 Manufacturer

AbbVie Inc

upadacitinibinformation